<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-084X</journal-id>
<journal-title><![CDATA[Nucleus]]></journal-title>
<abbrev-journal-title><![CDATA[Nucleus]]></abbrev-journal-title>
<issn>0864-084X</issn>
<publisher>
<publisher-name><![CDATA[CUBAENERGIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-084X2020000100022</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La imagen nuclear con anticuerpos monoclonales radiomarcados: viejas aplicaciones con nuevos enfoques]]></article-title>
<article-title xml:lang="en"><![CDATA[Nuclear imaging with radiolabeled monoclonal antibodies: old applications with new aproaches]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prats Capote]]></surname>
<given-names><![CDATA[Anaís]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leyva Montaña]]></surname>
<given-names><![CDATA[René]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Atiés Pérez]]></surname>
<given-names><![CDATA[Regla Caridad]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perera Pintado]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Isótopos  ]]></institution>
<addr-line><![CDATA[Playa La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<numero>67</numero>
<fpage>22</fpage>
<lpage>27</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-084X2020000100022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-084X2020000100022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-084X2020000100022&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los anticuerpos monoclonales marcados con radionucleidos fueron en sus inicios ampliamente empleados para el estudio de diversas enfermedades, fundamentalmente oncológicas mediante la inmunogammagrafía. Estos fueron poco a poco sustituidos por moléculas con mejores prestaciones como los péptidos y la 18F-fluordesoxiglucosa (18F-FDG). No obstante, en el presente siglo, la amplia introducción de la inmunoterapia produjo un cambio de paradigma en cuanto al empleo de los anticuerpos monoclonales radiomarcados para la adecuada selección y seguimiento de los pacientes a ser tratados con inmunoterapia, resurgiendo la inmunotomografía por emisión de fótón único (inmuno-SPECT), la inmunotomografía por emisión de positrones (inmuno-PET) y la imagen corregistrada con la tomografía axial computarizada (TAC), como modalidades de gran valor en el manejo del cáncer. El objetivo del presente trabajo fue brindar una panorámica acerca de la evolución de la imagen nuclear con anticuerpos monoclonales radiomarcados y sus principales aplicaciones en el tiempo, fundamentalmente en el estudio de los pacientes con cáncer.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract In the beginning, radionuclide-labeled monoclonal antibodies were widely employed for the study of various diseases, mainly oncological, by immunoscintigraphy. They were gradually replaced by molecules with better performance such as peptides and 18F-FDG. However, in the present century, the wide introduction of immunotherapy produced a paradigm shift in the use of radiolabeled monoclonal antibodies for the proper selection and follow-up of patients to be treated with immunotherapy, re-emerging of the immune-single photon emission tomography (immuno-SPECT), the immune-positron emission tomography (immuno-PET) and the co-registered image with computed tomography (CT) as imaging modalities of great value in the management of cancer. The aim of the present work was to provide an overview of the evolution of nuclear imaging with radiolabeled monoclonal antibodies and their main applications over the time, mainly in the study of patients with cancer.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[análisis radioinmunológico]]></kwd>
<kwd lng="es"><![CDATA[antígenos]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos]]></kwd>
<kwd lng="es"><![CDATA[tomografía de emisión computerizada de fotón único]]></kwd>
<kwd lng="es"><![CDATA[tomografía computerizada con positrón]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos monoclonales]]></kwd>
<kwd lng="es"><![CDATA[radioinmunoescintigrafía]]></kwd>
<kwd lng="en"><![CDATA[radioimmunoassay]]></kwd>
<kwd lng="en"><![CDATA[antigens]]></kwd>
<kwd lng="en"><![CDATA[antibodies]]></kwd>
<kwd lng="en"><![CDATA[single photon emission computed tomography]]></kwd>
<kwd lng="en"><![CDATA[positron computed tomography]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibodies]]></kwd>
<kwd lng="en"><![CDATA[radioimmunoscintigraphy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WU]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[SHU]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multimodal molecular imaging: current status and future directions]]></article-title>
<source><![CDATA[Contrast Media Mol Imaging]]></source>
<year>2018</year>
<volume>1382183</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FLEUREN]]></surname>
<given-names><![CDATA[EDG]]></given-names>
</name>
<name>
<surname><![CDATA[VERSLEIJEN-JONKERS]]></surname>
<given-names><![CDATA[YMH]]></given-names>
</name>
<name>
<surname><![CDATA[HESKAMP]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[VAN HERPEN]]></surname>
<given-names><![CDATA[CML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Theranostic applications of antibodies in oncology]]></article-title>
<source><![CDATA[Molecular Oncology]]></source>
<year>2014</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>799-812</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KHALIL]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[TREMOLEDA]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[BAYOMY]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[GSELL]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular SPECT imaging: an overview]]></article-title>
<source><![CDATA[International Journal of Molecular Imaging]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAILLY]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[BODET-MILIN]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[ROUSSEAU]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[FAIVRE-CHAUVET]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pretargeting for imaging and therapy in oncological nuclear medicine]]></article-title>
<source><![CDATA[EJNMMI Radiopharm Chem]]></source>
<year>2017</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHATAL]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[PELTIER]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[BARDIES]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[CHÉTANNEAU]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?]]></article-title>
<source><![CDATA[Eur J Nucl Med]]></source>
<year>1992</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>205-13</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BISCHOF DELALOYE]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[DELALOYE]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?]]></article-title>
<source><![CDATA[Eur J Nucl Med]]></source>
<year>1995</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>571-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BISCHOF DELALOYE]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[DELALOYE]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor imaging with monoclonal antibodies]]></article-title>
<source><![CDATA[Semin Nucl Med]]></source>
<year>1995</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>144-64</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HNATOWICH]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is Technetium-99m the radioisotope of choice for radioimmunoscintigraphy?]]></article-title>
<source><![CDATA[J Nucl Biol Med]]></source>
<year>1994</year>
<volume>38</volume>
<numero>4^sSuppl 1</numero>
<issue>4^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>22-32</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RAMOS]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[RODRÍGUEZ]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[OLIVA]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic efficacy and safety of 99mTc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas. Final report clinical trial Phase I/II]]></article-title>
<source><![CDATA[Cancer Biology &amp; Therapy]]></source>
<year>2007</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SOLANO]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[CANDEBAT]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoscintigraphic diagnosis of ovarian cancer with Tc-99m labeled MAb ior-c5: First Clinical Results]]></article-title>
<source><![CDATA[World J Nucl Med]]></source>
<year>2003</year>
<volume>2</volume>
<page-range>30-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LARSON]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radioimmunology. Imaging and therapy]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1991</year>
<volume>67</volume>
<numero>^s4 Suppl</numero>
<issue>^s4 Suppl</issue>
<supplement>4 Suppl</supplement>
<page-range>1253-60</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RAMOS]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[RODRÍGUEZ]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[OLIVA]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[IZNAGA]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[99mTc-labeled anti-human epidermal growth factor receptor antibody (ior egf/r3) in patients with tumor of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy]]></article-title>
<source><![CDATA[J. Nucl. Med.]]></source>
<year>1999</year>
<volume>40</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>768-75</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MELLER]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[LIERSCH]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[OEZERDEN]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[SAHLMANN]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting NCA-95 and other granulocyte antigens and receptors with radiolabeled monoclonal antibodies (Mabs)]]></article-title>
<source><![CDATA[Q J Nucl Med Mol Imaging]]></source>
<year>2010</year>
<volume>54</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>582-98</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOLDSMITH]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[SIGNORE]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine]]></article-title>
<source><![CDATA[Q J Nucl Med Mol Imaging]]></source>
<year>2010</year>
<volume>54</volume>
<page-range>574-81</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KINNE R]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[EMMRICH]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[FREESMEYER]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical impact of radiolabeled anti-CD4 antibodies in the diagnosis of rheumatoid arthritis]]></article-title>
<source><![CDATA[Q J Nucl Med Mol Imaging]]></source>
<year>2010</year>
<volume>54</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>629-38</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>[16]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZAYAS]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[FRAXEDAS]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[REYES]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del 99mTc-ior t3 como radiotrazador del rechazo agudo del trasplante renal]]></article-title>
<source><![CDATA[Rev Esp Med Nucl]]></source>
<year>1997</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>329-30</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>[17]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TORRES]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[HERNÁNDEZ]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin]]></article-title>
<source><![CDATA[Nucl Med Commun]]></source>
<year>2005</year>
<volume>26</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1049-57</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>[18]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEÑA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoscintigraphy and radioimmunotherapy in cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013)]]></article-title>
<source><![CDATA[MEDICC Review]]></source>
<year>2014</year>
<volume>16</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>55-60</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>[19]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KAUR]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[VENKTARAMAN]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[JAIN]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[SENAPATI]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent trends in antibody-based oncologic imaging]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2012</year>
<volume>315</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-111</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>[20]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VAN DONGEN]]></surname>
<given-names><![CDATA[GAMS]]></given-names>
</name>
<name>
<surname><![CDATA[VISSER]]></surname>
<given-names><![CDATA[GWM]]></given-names>
</name>
<name>
<surname><![CDATA[LUB DE HOOGE]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[DE VRIES]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immuno-PET: a navigator in monoclonal antibody development and applications]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2007</year>
<volume>12</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1379-89</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>[21]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAILLY]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[CLÉRY]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[FAIVRE]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[BOURGEOIS]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immuno-PET for clinical theranostic approaches]]></article-title>
<source><![CDATA[Int. J. Mol. Sci.]]></source>
<year>2017</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-68</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>[22]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TORNESELLO]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[BUONAGURO]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[TORNESELLO]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[BUONAGURO]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insights in the design of bioactive peptides and chelating agents for imaging and therapy in oncology]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2017</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1282</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>[23]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[THOMAS]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[TEICHER]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[HASSAN]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody-drug conjugates for cancer therapy]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2016</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>e254-62</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>[24]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HOLLINGSWORTH]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[JANSEN]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Turning the corner on therapeutic cancer vaccines]]></article-title>
<source><![CDATA[NPJ Vaccines]]></source>
<year>2019</year>
<volume>4</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>[25]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LAMBERTS]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[WILLIAMS]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[TERWISSCHA VAN SCHELTINGA]]></surname>
<given-names><![CDATA[AGT]]></given-names>
</name>
<name>
<surname><![CDATA[LUBDE HOOGE]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody positron emission tomography imaging in anticancer drug development]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1491-504</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>[26]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ALUICIO]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[ELLISON]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[BARNHART]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[CAI]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PET radiometals for antibody labeling]]></article-title>
<source><![CDATA[J Labelled Comp Radiopharm]]></source>
<year>2018</year>
<volume>61</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>636-51</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>[27]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KRAEBER]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[BAILLY]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[CHÉREL]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[CHATAL]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ImmunoPET to help stratify patients for targeted therapies and to improve drug development]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2016</year>
<volume>43</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2166-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>[28]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KUTOVA]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[GURYEV]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[SOKOLOVA]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[ALZEIBAK]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeted delivery to tumors: multidirectional strategies to improve treatment efficiency]]></article-title>
<source><![CDATA[Cancers]]></source>
<year>2019</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>[29]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GEBHART]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[LAMBERTS]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[WIMANA]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[GARCIA]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial]]></article-title>
<source><![CDATA[Ann. Oncol.]]></source>
<year>2016</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>619-24</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>[30]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEÑA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[CROMBET]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[PRATS]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoscintigraphy with 99mTc-Nimotuzumab for planning immunotherapy in patients with bone metastases due to prostate cancer]]></article-title>
<source><![CDATA[Clin Nucl Med]]></source>
<year>2016</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>244-6</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>[31]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEÑA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[CROMBET]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[VERGARA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoscintigraphy with 99mTc-14F7 and 99mTc-Nimotuzumab in patients with non-small cell lung cancer]]></article-title>
<source><![CDATA[Trends Cancer Res Chemother]]></source>
<year>2018</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>[32]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[TORRES]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[VERGARA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SPECT/CT: principales aplicaciones en la medicina nuclear]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2017</year>
<numero>62</numero>
<issue>62</issue>
<page-range>2-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>[33]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZHANG]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[HAO]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[WEIBO]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PET tracers based on Zirconium-89]]></article-title>
<source><![CDATA[Curr Radiopharm]]></source>
<year>2011</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>131-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>[34]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RÖSCH]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[HERZOG]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[QAIM]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y]]></article-title>
<source><![CDATA[Pharmaceuticals]]></source>
<year>2017</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>56</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>[35]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DIVGI]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[UZZO]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[GATSONIS]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[BARTZ]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: Results from the REDECT trial]]></article-title>
<source><![CDATA[J. Clin. Oncol.]]></source>
<year>2013</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187-94</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>[36]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MENDLER]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[GEHRING]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[WESTER]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[SCHWAIGER]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[89Zr-labeled versus 124I-labeled &#120572;HER2 fab with optimized plasma half-life for high-contrast tumor imaging in vivo]]></article-title>
<source><![CDATA[J. Nucl. Med.]]></source>
<year>2015</year>
<volume>56</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1112-8</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>[37]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BHATT]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[PANDYA]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[WADAS]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in Zirconium-89 chelator development]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2018</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>638</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>[38]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LIU]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides]]></article-title>
<source><![CDATA[Adv Drug Deliv Rev]]></source>
<year>2008</year>
<volume>60</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1347-70</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>[39]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[OSBORNE]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[GREEN]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[SPRATT]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[LYASHCHENKO]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective pilot study of 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy]]></article-title>
<source><![CDATA[J. Urol.]]></source>
<year>2014</year>
<volume>191</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1439-45</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>[40]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BORJESSON]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[JAUW]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
<name>
<surname><![CDATA[BOELLAARD]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[DE BREE]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2006</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2133-40</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>[41]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAHCE]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[HUISMAN]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[VERWER]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[OOIJEVAAR]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer]]></article-title>
<source><![CDATA[EJNMMI Res]]></source>
<year>2014</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>[42]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZALUTSKY]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2006</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1958-60</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>[43]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MENKE]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[GOOTJES]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[HUISMAN]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[VUGTS]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[89Zr-cetuximab PET imaging in patients with advanced colorectal cancer]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2015</year>
<volume>6</volume>
<numero>30</numero>
<issue>30</issue>
<page-range>30384-93</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>[44]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FOLLACCHIO]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[DE FEO]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[MONTELEONE]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[DE VINCENTIS]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiopharmaceuticals labelled with copper radionuclides: Clinical results in human beings]]></article-title>
<source><![CDATA[Curr. Radiopharm]]></source>
<year>2018</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-3</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>[45]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SASADA]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[KURIHARA]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[KINOSHITA]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[YOSHIDA]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[64Cu-DOTA-Trastuzumab PET imaging for HER2-specific primary lesions of breast cancer]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2017</year>
<volume>28</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2028-9</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>[46]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MORTIMER]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[BADING]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[PARK]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[FRANKEL]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor uptake of 64Cu-DOTA-trastuzumab in patients with metastatic breast cancer]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2018</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-43</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>[47]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAILLY]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[GOUARD]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[GUÉRARD]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[CHALOPIN]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What is the best radionuclide for Immuno-PET of multiple myeloma? A comparison study between 89Zr- and 64Cu-labeled Anti-CD138 in a preclinical syngeneic model]]></article-title>
<source><![CDATA[Int. J. Mol. Sci.]]></source>
<year>2019</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2564</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>[48]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ULANER]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[HYMAN]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[LYASHCHENKO]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[LEWIS]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[89Zr-Trastuzumab PET/CT for detection of human epidermal growth factor receptor 2-positive metastases in patients with human epidermal growth factor receptor 2-negative primary breast cancer]]></article-title>
<source><![CDATA[Clin Nucl Med]]></source>
<year>2017</year>
<volume>42</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>912-7</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>[49]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BERG]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[GILL]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[MARIK]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[OGASAWARA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[WILLIAMS]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Total-body PET and highly stable chelators together enable meaningful 89Zr-antibody-PET studies up to 30 days postinjection]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2020</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>453-60</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>[50]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TORRES]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[COCA]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[CASACÓ]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas]]></article-title>
<source><![CDATA[Nucl Med Comm]]></source>
<year>2008</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>66-75</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
